Efforts to rebalance investment and evidence generation towards primary prevention of preclinical and clinical obesity for communities and populations is imperative and must continue to ensure patients discharged after GLP-1/GIP treatment can return to an environment that supports weight maintenance and optimal physical and mental health. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.